Alternatives to BioMarin
BioMarin is a Biotechnology tool: a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to BioMarin
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
- Website
Travere Therapeutics51BiotechnologySan Diego, USA$63.0MA biopharmaceutical company focused on developing and commercializing therapies for rare diseases.
- Website
Viridian Therapeutics, Inc.43BiotechnologyWaltham, United States$350.0MBiopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.
- Website
SOLVE FSHD40BiotechnologyVancouver, Canada$9.2MVenture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Epicrispr Biotechnologies62BiotechnologySouth San Francisco, United States$90.0MEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
- EAEarendil Labs56BiotechnologyBeijing, China$787.0M
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
- Website
Cellares54BiotechnologySouth San Francisco, USA$327.0MThe first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.
- Website
Gossamer Bio54BiotechnologySan Diego, USA$150.0MA biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.
Showing the 20 closest matches. See the rest on the BioMarin profile.
Compare BioMarin head to head
Side by side on what each one does, what it costs, and what real users report.